Cargando…
Prevalence and Risk Factors for Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients From 14 Countries: Estimates of the INTERPRET-DD Study
Aim: Diabetic peripheral neuropathy (DPN) is a common, severe microvascular complication of diabetes. Our study was to assess prevalence and risk factors for DPN in subjects with type 2 diabetes from 14 different countries. Methods: A total of 2,733 subjects with type 2 diabetes aged 18–65 years (45...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606804/ https://www.ncbi.nlm.nih.gov/pubmed/33194943 http://dx.doi.org/10.3389/fpubh.2020.534372 |
_version_ | 1783604513847902208 |
---|---|
author | Lu, Yanhui Xing, Pengbo Cai, Xue Luo, Dan Li, Ruxue Lloyd, Cathy Sartorius, Norman Li, Mingzi |
author_facet | Lu, Yanhui Xing, Pengbo Cai, Xue Luo, Dan Li, Ruxue Lloyd, Cathy Sartorius, Norman Li, Mingzi |
author_sort | Lu, Yanhui |
collection | PubMed |
description | Aim: Diabetic peripheral neuropathy (DPN) is a common, severe microvascular complication of diabetes. Our study was to assess prevalence and risk factors for DPN in subjects with type 2 diabetes from 14 different countries. Methods: A total of 2,733 subjects with type 2 diabetes aged 18–65 years (45.3% men, mean duration of diabetes = 8.8 years) were included to perform this International Prevalence and Treatment of Diabetes and Depression (INTERPRET-DD) study in 14 countries. After a structured questionnaire was used in face-to-face interviews to collect sociodemographic characteristics and medical records of the participating subjects, laboratory tests were carried out for clinical measurement. Depressive symptoms were diagnosed and measured using the Patient Health Questionnaire-9. The potential risk factors for DPN were determined by multilevel mixed-effects logistic regression, accounting for clustering of participants within the country. Robustness of the estimates was assessed by sensitivity analysis. Results: The overall prevalence of DPN across different countries was 26.71%, whereas country-specific prevalences showed considerable variation. Multivariate analysis revealed that duration of diabetes (OR: 1.08 per 1-year increase, 95% CI: 1.06–1.09), poor glycemic control (OR: 1.11 per 1% increase in HbA1c, 95% CI: 1.05–1.18), and history of hypertension (OR: 1.58, 95% CI: 1.18–2.12), cardiovascular disease (OR: 2.07, 95% CI: 1.55–2.78) and depressive symptoms (OR: 1.92, 95% CI: 1.43–2.58) were independently and positively associated with the risk of DPN. Sensitivity analyses including or excluding patients from countries with extreme low or high prevalence of DPN yielded similar estimates in terms of trend and magnitude. Conclusions: This international study illustrates that more than a quarter of individuals with type 2 diabetes developed DPN. The prevalence was positively associated with the duration of diabetes, poor glycemic control, and history of hypertension, cardiovascular disease and depressive symptoms. |
format | Online Article Text |
id | pubmed-7606804 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76068042020-11-13 Prevalence and Risk Factors for Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients From 14 Countries: Estimates of the INTERPRET-DD Study Lu, Yanhui Xing, Pengbo Cai, Xue Luo, Dan Li, Ruxue Lloyd, Cathy Sartorius, Norman Li, Mingzi Front Public Health Public Health Aim: Diabetic peripheral neuropathy (DPN) is a common, severe microvascular complication of diabetes. Our study was to assess prevalence and risk factors for DPN in subjects with type 2 diabetes from 14 different countries. Methods: A total of 2,733 subjects with type 2 diabetes aged 18–65 years (45.3% men, mean duration of diabetes = 8.8 years) were included to perform this International Prevalence and Treatment of Diabetes and Depression (INTERPRET-DD) study in 14 countries. After a structured questionnaire was used in face-to-face interviews to collect sociodemographic characteristics and medical records of the participating subjects, laboratory tests were carried out for clinical measurement. Depressive symptoms were diagnosed and measured using the Patient Health Questionnaire-9. The potential risk factors for DPN were determined by multilevel mixed-effects logistic regression, accounting for clustering of participants within the country. Robustness of the estimates was assessed by sensitivity analysis. Results: The overall prevalence of DPN across different countries was 26.71%, whereas country-specific prevalences showed considerable variation. Multivariate analysis revealed that duration of diabetes (OR: 1.08 per 1-year increase, 95% CI: 1.06–1.09), poor glycemic control (OR: 1.11 per 1% increase in HbA1c, 95% CI: 1.05–1.18), and history of hypertension (OR: 1.58, 95% CI: 1.18–2.12), cardiovascular disease (OR: 2.07, 95% CI: 1.55–2.78) and depressive symptoms (OR: 1.92, 95% CI: 1.43–2.58) were independently and positively associated with the risk of DPN. Sensitivity analyses including or excluding patients from countries with extreme low or high prevalence of DPN yielded similar estimates in terms of trend and magnitude. Conclusions: This international study illustrates that more than a quarter of individuals with type 2 diabetes developed DPN. The prevalence was positively associated with the duration of diabetes, poor glycemic control, and history of hypertension, cardiovascular disease and depressive symptoms. Frontiers Media S.A. 2020-10-20 /pmc/articles/PMC7606804/ /pubmed/33194943 http://dx.doi.org/10.3389/fpubh.2020.534372 Text en Copyright © 2020 Lu, Xing, Cai, Luo, Li, Lloyd, Sartorius and Li. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Public Health Lu, Yanhui Xing, Pengbo Cai, Xue Luo, Dan Li, Ruxue Lloyd, Cathy Sartorius, Norman Li, Mingzi Prevalence and Risk Factors for Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients From 14 Countries: Estimates of the INTERPRET-DD Study |
title | Prevalence and Risk Factors for Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients From 14 Countries: Estimates of the INTERPRET-DD Study |
title_full | Prevalence and Risk Factors for Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients From 14 Countries: Estimates of the INTERPRET-DD Study |
title_fullStr | Prevalence and Risk Factors for Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients From 14 Countries: Estimates of the INTERPRET-DD Study |
title_full_unstemmed | Prevalence and Risk Factors for Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients From 14 Countries: Estimates of the INTERPRET-DD Study |
title_short | Prevalence and Risk Factors for Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients From 14 Countries: Estimates of the INTERPRET-DD Study |
title_sort | prevalence and risk factors for diabetic peripheral neuropathy in type 2 diabetic patients from 14 countries: estimates of the interpret-dd study |
topic | Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606804/ https://www.ncbi.nlm.nih.gov/pubmed/33194943 http://dx.doi.org/10.3389/fpubh.2020.534372 |
work_keys_str_mv | AT luyanhui prevalenceandriskfactorsfordiabeticperipheralneuropathyintype2diabeticpatientsfrom14countriesestimatesoftheinterpretddstudy AT xingpengbo prevalenceandriskfactorsfordiabeticperipheralneuropathyintype2diabeticpatientsfrom14countriesestimatesoftheinterpretddstudy AT caixue prevalenceandriskfactorsfordiabeticperipheralneuropathyintype2diabeticpatientsfrom14countriesestimatesoftheinterpretddstudy AT luodan prevalenceandriskfactorsfordiabeticperipheralneuropathyintype2diabeticpatientsfrom14countriesestimatesoftheinterpretddstudy AT liruxue prevalenceandriskfactorsfordiabeticperipheralneuropathyintype2diabeticpatientsfrom14countriesestimatesoftheinterpretddstudy AT lloydcathy prevalenceandriskfactorsfordiabeticperipheralneuropathyintype2diabeticpatientsfrom14countriesestimatesoftheinterpretddstudy AT sartoriusnorman prevalenceandriskfactorsfordiabeticperipheralneuropathyintype2diabeticpatientsfrom14countriesestimatesoftheinterpretddstudy AT limingzi prevalenceandriskfactorsfordiabeticperipheralneuropathyintype2diabeticpatientsfrom14countriesestimatesoftheinterpretddstudy |